Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Preferred Shares (2022)

Lexeo Therapeutics' Preferred Shares history spans 1 years, with the latest figure at $185.6 million for Q4 2022.

  • On a quarterly basis, Preferred Shares changed N/A to $185.6 million in Q4 2022 year-over-year; TTM through Dec 2022 was $185.6 million, a N/A change, with the full-year FY2022 number at $185.6 million, changed N/A from a year prior.
  • Preferred Shares hit $185.6 million in Q4 2022 for Lexeo Therapeutics.
  • Over the last five years, Preferred Shares for LXEO hit a ceiling of $185.6 million in Q4 2022 and a floor of $185.6 million in Q4 2022.